Mark S Todtenkopf
Overview
Explore the profile of Mark S Todtenkopf including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
939
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McIntyre R, Harris M, Todtenkopf M, Akerman S, Burgett J
CNS Spectr
. 2024 Nov;
29(6):542-548.
PMID: 39582163
Opioid antagonists block opioid receptors, a mechanism associated with utility in several therapeutic indications. Here, we review the sites of action, clinical uses, pharmacology, and general safety profiles of US...
2.
Todtenkopf M, Correll C, Harris-White M, Doane M, McDonnell D
Ment Health Clin
. 2023 Oct;
13(4):196-197.
PMID: 37860589
No abstract available.
3.
Correll C, Hojlund M, Graham C, Todtenkopf M, McDonnell D, Simmons A
Int J Neuropsychopharmacol
. 2023 Jun;
26(7):451-464.
PMID: 37326421
Background: Patients with first-episode psychosis or early-phase schizophrenia are susceptible to olanzapine-associated weight gain and cardiometabolic dysregulation. This meta-analysis characterized weight and metabolic effects observed during olanzapine treatment in randomized...
4.
McIntyre R, Citrome L, Cummings H, Todtenkopf M, Tan L, White M, et al.
CNS Spectr
. 2022 Mar;
28(3):288-299.
PMID: 35236531
Background: The endogenous opioid system affects metabolism, including weight regulation. Evidence from preclinical and clinical studies provides a rationale for targeting this system to mitigate weight-related side effects of antipsychotics....
5.
An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder
Citrome L, Graham C, Simmons A, Jiang Y, Todtenkopf M, Silverman B, et al.
Neuropsychiatr Dis Treat
. 2021 Sep;
17:2885-2904.
PMID: 34526769
Olanzapine effectively treats schizophrenia and bipolar I disorder (BD-I); however, its use is limited by the risk of significant weight gain and metabolic effects. OLZ/SAM, a combination of olanzapine and...
6.
Cunningham J, Todtenkopf M, Dean R, Azar M, Koob G, Deaver D, et al.
Pharmacol Biochem Behav
. 2021 Mar;
204:173157.
PMID: 33647274
Opioid receptors modulate neurochemical and behavioral responses to drugs of abuse in nonclinical models. Samidorphan (SAM) is a new molecular entity that binds with high affinity to human mu- (μ),...
7.
Pathak S, Jiang Y, DiPetrillo L, Todtenkopf M, Liu Y, Correll C
J Clin Psychiatry
. 2020 Mar;
81(2).
PMID: 32220153
Objective: Patients with schizophrenia and comorbid alcohol use disorder remain understudied. This post hoc analysis evaluated data from Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness in Schizophrenia...
8.
Puryear C, Brooks J, Tan L, Smith K, Li Y, Cunningham J, et al.
Neurosci Biobehav Rev
. 2019 Dec;
108:658-678.
PMID: 31821832
Major depressive disorder (MDD) is a heterogeneous clinical syndrome involving distinct pathological processes. Core features of MDD include anhedonia, reduced motivation, increased anxiety, negative affective bias, cognitive impairments, and dysregulated...
9.
Citrome L, McEvoy J, Todtenkopf M, McDonnell D, Weiden P
Neuropsychiatr Dis Treat
. 2019 Oct;
15:2559-2569.
PMID: 31564881
Olanzapine is a second-generation atypical antipsychotic with proven efficacy for the treatment of schizophrenia. Approved in 1996, olanzapine is one of the most studied antipsychotics, resulting in a considerable amount...
10.
Cunningham J, Eyerman D, Todtenkopf M, Dean R, Deaver D, Sanchez C, et al.
J Psychopharmacol
. 2019 Jul;
33(10):1303-1316.
PMID: 31294646
Background: Olanzapine, regarded as one of the most efficacious antipsychotic medications for the treatment of schizophrenia, is associated with a high risk of weight gain and metabolic dysfunction. ALKS 3831,...